|
|
|
|
| LEADER |
01778nmm a2200385 u 4500 |
| 001 |
EB002003328 |
| 003 |
EBX01000000000000001166229 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
211020 ||| eng |
| 100 |
1 |
|
|a Diamond, Michael S.
|
| 245 |
0 |
0 |
|a SARS-CoV-2 monoclonal antibody testing in vivo
|h Elektronische Ressource
|c an interview with Michael S. Diamond
|
| 260 |
|
|
|a London
|b Henry Stewart Talks
|c 2021, 2021
|
| 300 |
|
|
|a 1 streaming audio file (8 min.))
|
| 505 |
0 |
|
|a Contents: Work done in the lab to test monoclonal antibody efficacy in vivo -- How the antibodies are chosen for testing -- Work done on possible future SARS-CoV-2 mutations -- Combating neutralisation escape -- Working towards broadly neutralising antibodies -- Future work for this research
|
| 653 |
|
|
|a SARS-CoV-2 / immunology
|
| 653 |
|
|
|a COVID-19 / prevention & control
|
| 653 |
|
|
|a COVID-19 (Disease) / Treatment
|
| 653 |
|
|
|a Coronavirus infections / Immunological aspects
|
| 653 |
|
|
|a Spike Glycoprotein, Coronavirus / immunology
|
| 653 |
|
|
|a Antiviral agents / Development
|
| 653 |
|
|
|a Monoclonal antibodies / Research
|
| 653 |
|
|
|a COVID-19 / immunology
|
| 653 |
|
|
|a COVID-19 (Disease) / Research
|
| 653 |
|
|
|a Monoclonal antibodies / Therapeutic use
|
| 653 |
|
|
|a Broadly Neutralizing Antibodies / immunology
|
| 653 |
|
|
|a Mutation
|
| 653 |
|
|
|a Antibodies, Monoclonal / immunology
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b HST
|a Henry Stewart Talks
|
| 490 |
0 |
|
|a Research and clinical interviews
|
| 500 |
|
|
|a Audio interview. - Title from title frames. - Mode of access: World Wide Web
|
| 856 |
4 |
0 |
|u https://hstalks.com/bs/4742
|x Verlag
|z Streaming video file
|
| 856 |
4 |
2 |
|u https://hstalks.com/bs/p/1060
|3 Series
|
| 082 |
0 |
|
|a 570
|